Clinician's Roundtable

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Brian Smith, MD, MPH According to the current recommendations, we should be testing all patients with COPD for alpha-1 antitrypsin deficiency (AATD). But unfortunately, there are many barriers that can keep us from following these recommendations. That’s why Dr. Brian Smith joins Dr. Charles Turck to share strategies for addressing those barriers and proactively detecting AATD in patients with COPD. Dr. Smith specializes in Family Medicine and Hospice and Palliative Medicine at Versailles Family Medicine in Kentucky. Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: David C. Mares, MD It’s absolutely critical to proactively detect alpha-1 antitrypsin deficiency (AATD) in our patients with COPD, but it’s just as important to know how to manage patients with this deficiency once we reach a diagnosis. That’s why Dr. David Mares joins Dr. Charles Turck to share his experiences and a patient case in managing AATD-associated COPD. Dr. David Mares is an adult pulmonology and critical care specialist at Ascension St. Vincent Anderson Hospital in Indiana. Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: David C. Mares, MD Several different professional organizations have created guidelines for screening for alpha-1 antitrypsin deficiency (AATD) in COPD that can help us proactively detect and treat patients. Joining Dr. Charles Turck to break down those various guideline recommendations and share best practices for implementing them into clinical practice is Dr. David Mares, who specializes in adult pulmonology and critical care in Anderson, Indiana. Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

Host: Jonathan Chung, MD Host: Seth Kligerman, MD Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.

Guest: Ina Park, MD The United States has seen its largest increase in syphilis cases in the past five years. And with increases prevalent in every region, along with a shortage of medication, additional surveillance strategies and importation resources are necessary. Dive in for a discussion on the challenges and strategies to combat the spread of syphilis with Dr. Ina Park, Professor of Family Community Medicine at the University of California San Francisco School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Melanie Dispenza, MD The future therapeutic landscape for food allergy prevention is looking clearer as a drug typically used to treat hematologic malignancies has shown to prevent systemic anaphylaxis to allergens and increase patients' tolerance to peanuts. Along with this, other therapies are also in development for allergy treatment. To learn more, join Dr. Charles Turck as he dives deeper into this study and its findings with Dr. Melanie Dispenza, Assistant Professor of Medicine at Johns Hopkins University School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Henry Rosenberg, MD Malignant hyperthermia is an inherited disorder primarily recognized by anesthesia professionals. And since this condition can have significant consequences on a patient’s health, including their likelihood of surviving surgery, it’s important to know how to diagnose and treat malignant hyperthermia emergencies in operating room settings. Join Dr. Charles Turck as he dives deeper into this topic with Dr. Henry Rosenberg, a member of the Board of Directors of the Malignant Hyperthermia Association of the United States.

Host: Matt Birnholz, MD Guest: Donald Kohn, MD Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentiviral vectors in various gene therapy applications. Learn more about the development, efficacy, and safety of third-generation lentiviral vectors with Dr. Matt Birnholz and Dr. Donald Kohn, Distinguished Professor at the University of California, Los Angeles. This non-certified educational series is produced and controlled by ReachMD, and is intended for healthcare professionals only.

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Christin Iroegbu PhD, RN If left untreated, chronic kidney disease (CKD) can progress to end-stage renal disease, requiring dialysis or kidney transplant as the only treatment options. So communicating this to patients, along with chronic conditions that could contribute to this are key. To learn more about raising awareness of the causes of CKD and to help slow the progression, join Dr. Mary Katherine Cheeley who’s speaking with Dr. Iroegbu, Co-Author of the article published in the Journal of Advanced Nursing, titled “An Integrative Review: Chronic Kidney Disease Awareness and the Social Determinants of Health Equity,” and T32 Postdoctoral Research Fellow at the Center for Health Outcomes and Policy Research at the University of Pennsylvania School of Nursing.

Host: Jennifer Caudle, DO Guest: Sayantani Sindher, MD Recently, Omalizumab was studied in patients due to the avoidance of management and guidance when it comes to treating food allergies in children and adults. According to this doctor, approximately 45 percent of patients seen in his clinic have multi-food allergies that are not being met with current treatment options. So to explain his research, Dr. Jennifer Caudle is joined by Dr. Sayantani Sinder, Clinical Associate Professor of Medicine and Pediatric Allergy and Clinical Immunology Physician at Stanford Healthcare and Stanford Medicine Children’s Health.

Host: Tauseef Ali, MD, FACG, AGAF Host: Sabina Ali, MD Host: Neil Nandi, MD, FACP Host: Tina Aswani-Omprakash, MPH A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Brian P. McDonough, MD, FAAFP Pediatric patients who have allergies could have a higher chance of running into other issues, such as asthma and things that can become more serious. So earlier intervention and treatments could decrease the likelihood of running into secondary issues. To learn more about addressing the root cause of allergies, join Dr. Charles Turck as he speaks with Dr. Brian McDonough, Clinical Professor of Family Medicine at Temple University School of Medicine and the Chairman of the Department of Family Medicine at St. Francis Hospital in Wilmington, DE.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Brian P. McDonough, MD, FAAFP One of the most important things you can do as a clinician providing care to your patients with allergies is taking time to educate them, their family, or caregivers on the factors that could possibly be causing the allergies and discussing steps on how they can improve it. So to dive into some of these strategies and best practices, join Dr. Charles Turck as he speaks with Dr. Brian McDonough, Clinical Professor of Family Medicine at Temple University School of Medicine and Chairman of the Department of Family Medicine at St. Francis Hospital in Wilmington, Delaware.

Guest: Douglas Jones, MD A recent study was done to show the side effects of diphenhydramine for allergic reactions, and one of the main detriments was that it could impair the patient by making them tired or sleepy. Another finding was that it doesn’t work that quickly, so in turn, giving diphenhydramine in a severe allergic reaction could cause more harm than good. To learn more on what you should know before using diphenhydramine in allergic reaction situations and possible better solutions, tune in with Dr. Douglas Jones, Board-Certified Allergist and Immunologist with the Tanner Clinic in Layton, Utah.

Host: Javed Butler, MD, MBA, MPH Guest: Jeffrey Wilson, MD There’s a decent amount of evidence showing allergic immune responses could have connections with heart disease. But with the knowledge gaps that exist, a need for bigger cohorts is necessary to get more information and data. So to explore the link between allergic reactions from food and heart disease, Dr. Javed Butler is joined by Dr. Jeffrey Wilson, Allergist and Immunologist in the Department of Medicine’s Division of Asthma, Allergy, and Immunology at the University of Virginia.

Guest: Gates B. Colbert, MD, FASN A class of medications called SGLT2 inhibitors have been proven to make a major difference for patients with chronic kidney disease (CKD) with and without diabetes when added to angiotensin converting enzyme (ACE) and angiotensin receptor blockers (ARB) classes of medications. Several medications that have been well studied and approved by the FDA in the United States have shown progression of not only CKD but also cardiovascular events and overall mortality. To learn more about these medications, join Dr. Gates Colbert, Assistant Clinical Professor of Medicine at Texas A&M College of Medicine, and Nephrologist and Certified Hypertension Specialist at Kidney and Hypertension Associates of Dallas.

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Clinicians experiencing substance abuse disorder (SUD) may have some reluctance about utilizing a Physician Health Program; however, it’s important to know what your resources are in terms of formal treatment and to seek a psychiatrist with addiction specialization. Dive into part two of this discussion to learn more about the valuable resources and programs that can help physicians recover from SUD with Dr. Michael Greenberg and Dr. Chris Bundy, Executive Medical Director of the Washington Physicians Health Program and Clinical Assistant Professor of Psychiatry at the University of Washington School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John Hertig PharmD, MS, CPPS Here in the United States, we're investing a little more into cost effectiveness to make the best use of very limited healthcare resources. When ready-to-administer (RTA) syringe products were compared against traditional vial and syringe, there was a significant holistic cost effectiveness benefit. So what other benefits do we need to know about? Dive in with Dr. Charles Turck for a comprehensive review of RTA prefilled syringes with Dr. John Hertig, Vice Chair and Associate Professor of Pharmacy Practice at Butler University College of Pharmacy and Health Sciences in Indianapolis.